At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓CD4 count ≥200 cells/μL
- ✓Viral load <50 copies/mL (undetectable)
- ✓On efavirenz + tenofovir + (lamivudine or emtricitabine) for ≥90 days prior to screening
- ✕Detectable HIV RNA on ultrasensitive assay within 90 days before screening
- ✕Prior evidence of intermediate or high-level resistance to efavirenz, tenofovir, or cytidine analogues
- ✕Hepatitis B infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Trial of a Weekly Schedule of Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment (5/2 Intermittent Treatment Schedule) Versus Continuous Treatment in Individuals With Virologic Suppression on This Combination
In Brief
A Phase 4 clinical trial evaluating Intermitent Dosing for HIV Infections. Completed, enrolled 60 participants across 7 sites.
Detailed Summary
For people with HIV who are currently taking specific medications (including Sustiva (efavirenz)) and have no detectable viral load, this study tracks how patients do if they take their medications for five days of the week compared with seven days of the week.
Study Details
Timeline
Interventions
Intermittent dosing treatment is the maintenance of the "5/2" schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. .